Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/Formoterol vs Salmeterol/Fluticasone in COPD
NCT01908140Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of aclidinium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Sep 2013; status: completed.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01908140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908140.